NuView Life Sciences

Binary cancer diagnostics and theranostics,
improving patient outcomes and reducing healthcare costs.

NuView Life Sciences is working to improve the way cancer is diagnosed and treated for our modern healthcare system.

NuView Life Sciences is creating binary cancer diagnostics and Theranostics to improve patient outcomes and reducing healthcare costs.

Led by a multi-disciplinary team of industry experts with decades of combined experience in healthcare and medical imaging technologies, NuView Life Sciences is poised to change how we look for and respond to cancer.

NuView Life Sciences has a strong mission – to change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.

Diagnostics

NuView Life Sciences’s leading technology, NV-VPAC1TM consists of a series of peptide analogs that target the vasoactive intestinal peptide receptor type 1 (VPAC1). The VPAC1 receptor becomes overexpressed in certain key malignancies including breast, prostate, colon, bladder, and endometrial cancer.

In Vivo Diagnostics

a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer

In Vitro Diagnostics

an in vitro diagnostic kit that may be used for detecting shed prostate and bladder cancer cells in voided urine

Theranostics Applications

NuView is preparing to expand its portfolio for Theranostics applications using the NV-VPAC1TM peptide analog…

From the Press

News

Molecular theranostics: prostate cancer and neuroendocrine tumor treatment gets personal

Prostate cancer is far more prevalent than neuroendocrine tumors. The American Cancer Society estimates that there will be about 161,360 new cases of prostate cancer…
NuView Life Sciences in the News

Decreasing Breast Cancer False Positives with NV-VPAC1-PET Scan Technology

Despite technological advancements in the healthcare industry, breast cancer remains a major health problem. Self-examination and annual screening mammograms continue to be the most common methods used for early…
NuView Life Sciences in the News

Retired US Air Force Fighter Pilots Develop Prostate Cancer at Alarming Rates

Screening frequency is being questioned; Innovations needed Questions around the rise in cancers in former Air Force pilots are causing concerns about the role of…

Get Answers From the National Cancer Institute

Information specialists at NCI’s Cancer Information Service (CIS), NCI’s contact center, are available to help answer your cancer-related questions whether you are a patient, family member or friend, health care provider, or researcher. The service is available in English and Spanish.